Key result
Genetically determined lower LDL-C is linked to weaker protection against ischemic stroke than CHD.
Observational (n=73,190)
No takes yet. Share an insight, caveat, or question.
OBJECTIVE: To examine the causal relevance of lifelong differences in low-density lipoprotein cholesterol (LDL-C) for ischemic stroke (IS) relative to that for coronary heart disease (CHD) using a Mendelian randomization approach. METHODS: We undertook a 2-sample Mendelian randomization, based on summary data, to estimate the causal relevance of LDL-C for risk of IS and CHD. Information from 62 independent genetic variants with genome-wide significant effects on LDL-C levels was used to estimate the causal effects of LDL-C for IS and IS subtypes (based on 12,389 IS cases from METASTROKE) and for CHD (based on 60,801 cases from CARDIoGRAMplusC4D). We then assessed the effects of LDL-C on IS and CHD for heterogeneity. RESULTS: ) when compared with that for CHD. CONCLUSIONS: In contrast with the consistent effects of LDL-C-lowering therapies on IS and CHD, genetic variants that confer lifelong LDL-C differences show a weaker effect on IS than on CHD. The relevance of etiologically distinct IS subtypes may contribute to the differences observed.
Valdés‐Márquez et al. (2019) conducted an observational in Ischemic stroke and coronary heart disease (n=73,190). Lifelong differences in low-density lipoprotein cholesterol (LDL-C) vs. Lower or normal LDL-C levels was evaluated on Risk of ischemic stroke relative to coronary heart disease. Lifelong LDL-C differences conferred by genetic variants showed a weaker effect on the risk of ischemic stroke than on coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: